Envestnet Asset Management
IRWD icon

Envestnet Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Envestnet Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,728
Closed -$39.3K – 4500
2025
Q1 		$39.3K Buy
26,728
+15,456
+137% +$36.8K ﹤0.01% 4306
2024
Q4 		$49.9K Buy
+11,272
New +$45.7K ﹤0.01% 4263
2024
Q3 		– Sell
-18,935
Closed -$123K – 4269
2024
Q2 		$123K Buy
18,935
+2,223
+13% +$15.7K ﹤0.01% 4026
2024
Q1 		$146K Buy
16,712
+5,885
+54% +$71.4K ﹤0.01% 4014
2023
Q4 		$124K Sell
10,827
-164
-1% -$1.62K ﹤0.01% 3921
2023
Q3 		$106K Sell
10,991
-233,928
-96% -$2.29M ﹤0.01% 3866
2023
Q2 		$2.61M Sell
244,919
-261,035
-52% -$2.81M ﹤0.01% 2113
2023
Q1 		$2.23M Buy
505,954
+281,820
+126% +$3.16M ﹤0.01% 2129
2022
Q4 		$2.78M Buy
224,134
+9,778
+5% +$111K ﹤0.01% 1957
2022
Q3 		$2.22M Sell
214,356
-3,458
-2% -$39.2K ﹤0.01% 2021
2022
Q2 		$2.51M Buy
217,814
+21,205
+11% +$250K ﹤0.01% 1960
2022
Q1 		$2.47M Buy
196,609
+42,606
+28% +$488K ﹤0.01% 2076
2021
Q4 		$1.8M Buy
154,003
+84,215
+121% +$1.03M ﹤0.01% 2248
2021
Q3 		$911K Buy
69,788
+15,210
+28% +$197K ﹤0.01% 2610
2021
Q2 		$702K Buy
54,578
+3,032
+6% +$34.7K ﹤0.01% 2761
2021
Q1 		$576K Sell
51,546
-173
-0.3% -$1.83K ﹤0.01% 2762
2020
Q4 		$589K Buy
51,719
+10,893
+27% +$119K ﹤0.01% 2575
2020
Q3 		$367K Sell
40,826
-56,850
-58% -$565K ﹤0.01% 2636
2020
Q2 		$1.01M Buy
97,676
+46,492
+91% +$476K ﹤0.01% 1968
2020
Q1 		$516K Sell
51,184
-33,204
-39% -$390K ﹤0.01% 2218
2019
Q4 		$1.12M Buy
+84,388
New +$930K ﹤0.01% 1952
2018
Q1 		– Sell
-1,077
Closed -$14K – 2896
2017
Q4 		$14K Hold
1,077
– – ﹤0.01% 2568
2017
Q3 		$14K Buy
1,077
+436
+68% +$6K ﹤0.01% 2543
2017
Q2 		$10K Buy
+641
New +$9.31K ﹤0.01% 2705
2014
Q4 		– Sell
-119
Closed -$1K – 2618
2014
Q3 		$1K Buy
+119
New +$1.36K ﹤0.01% 2612

Other funds holding IRWD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Envestnet Asset Management's IRWD Position: Q2 2025 in Review

Envestnet Asset Management sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2025, closing a stake of 26,728 shares — an estimated $39.3K sold.

Envestnet Asset Management first reported a position in IRWD in Q3 2014 and held it in 25 quarters. The position peaked at $2.78M in Q4 2022. 155 funds tracked by Wall St. Rank hold IRWD as of Q2 2025.

  • Envestnet Asset Management reported no remaining Ironwood Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 26,728 Ironwood Pharmaceuticals shares in Q2 2025, an estimated $39.3K.
  • Envestnet Asset Management first reported a position in Ironwood Pharmaceuticals in Q3 2014 and held it in 25 quarters.
  • Envestnet Asset Management's Ironwood Pharmaceuticals position peaked at $2.78M in Q4 2022.
  • 155 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2025.

Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.